Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor-selective agonists.
Introduction
Individuals with obesity are at high risk for type 2 diabetes mellitus (T2DM), cardiovascular disease and non-alcoholic steatohepatitis. Few pharmacotherapeutics have been approved for the treatment of obesity: they have limited efficacy and side effects (Kim et al., 2014; Valsamakis et al., 2017) . Gut hormone peptides have received attention as novel drug targets for obesity treatment, since peptide-based drugs show great promise owing to their high specificity to the intended targets when compared with small molecules (Mcgavigan and Murphy, 2012) . For example, the glucagonlike peptide-1 (GLP-1) analogue liraglutide, which has been used as a type 2 diabetes drug, has recently been approved for the treatment of obesity and leads to sustained weight loss (Campbell and Drucker, 2013; Kakkar and Dahiya, 2015) .
Neuromedin U (NmU) is a brain-gut peptide initially isolated from porcine spinal cord based on the contractile activity of rat uterine smooth muscle (Minamino et al., 1985) and expressed in both central and peripheral tissues (Ballesta et al., 1988; Fujii et al., 2000; Mitchell et al., 2009; Nakashima et al., 2010) . NmU is involved in various biological functions including energy homeostasis regulation (Brighton et al., 2004; Mitchell et al., 2009; Martinez and O'Driscoll, 2015) . Importantly, a relationship has been suggested between NmU gene polymorphisms and obesity in humans (Hainerová et al., 2006) . Intraventricularly administered NmU inhibits food intake (FI) and enhances energy metabolism in rats (Howard et al., 2000; Nakazato et al., 2000) . NmU transgenic mice exhibit reduced FI and a lean phenotype (Kowalski et al., 2005) , while NmU knockout (KO) mice exhibit obesity accompanied by increased FI and decreased locomotor activity and energy expenditure (Hanada et al., 2004) . Pro-opiomelanocortin (POMC; ACTH) and corticotropin-releasing hormone (CRH) may act downstream of NmU (Hanada et al., 2004) .
Two GPCRs, NMU1 and NMU2 receptors, have been identified as high-affinity receptors for NmU and are primarily expressed in the gastrointestinal tract and CNS respectively Hosoya et al., 2000; Szekeres et al., 2000; Graham et al., 2003) . Previous studies suggest that the NMU1 receptor is responsible for the action of peripherally administered NmU (Peier et al., 2011) . However, the body weights (BWs) of NMU2 receptor-KO mice are not different from those of wild-type mice fed normal diets (Zeng et al., 2006; Peier et al., 2009) , although the anti-obesity action of centrally administered NmU is mediated through NMU2, not NMU1 receptors (Peier et al., 2009) . Knockdown of NMU2 receptors in the paraventricular nucleus (PVN) of adult rats results in increased FI and BW gain when they were fed a high-fat diet (HFD) (Benzon et al., 2014) , highlighting the importance of the NMU2 receptor in the PVN for feeding and BW control. In contrast to central NmU, few reports address the mechanisms of action of peripheral NmU on neuronal activation in the brain. In fact, only one recent report shows that peripheral NmU decreases the levels of c-Fos, which is a marker of neuronal activation, in the PVN and dorsal raphe nucleus of rats to regulate motivation for food (Mccue et al., 2017) .
Despite advances in understanding NmU and NMU1/2 function, the optimal selective or non-selective NMU1/2 receptor agonists for the treatment of obesity and diabetes remain unclear. Recently, long-acting NmU analogues conjugated with polyethylene glycol (PEG) (Ingallinella et al., 2012) , human serum albumin (HSA) (Neuner et al., 2014) or palmitate (Dalbøge et al., 2015a) have been developed. Peripherally administered PEG-NmU and HSA-NmU exert their effects via both NMU1 and NMU2 receptors (Ingallinella et al., 2012; Neuner et al., 2014) , while peripheral native NmU acts exclusively through NMU1 receptors (Peier et al., 2011) . Thus, long-acting NmU analogues exert anorectic effects via mechanisms of action distinct from those of the short-lived native NmU (Ingallinella et al., 2012; Neuner et al., 2014) . In addition, these NmU analogues are nonselective for NMU1 versus NMU2 receptors. More recently, the discovery of hexapeptides selective for NMU1 and NMU2 receptors has been reported (Takayama et al., 2015; ; however, these substances are short lived, and their effects have not been fully investigated in vivo. Furthermore, it is not clear whether the long-acting NmU analogues have any unwanted adverse effects.
This study aimed to clarify the pharmacological and unwanted effects of long-acting non-selective NMU1/2 receptor agonists NMU-0002 (Inooka et al., 2017) and NMU-6014, an NMU1 receptor-selective agonist NMU-6102 and an NMU2 receptor-selective agonist NMU-2084 in diet-induced obese (DIO) mice and diabetic ob/ob mice. Additionally, our study aimed to reveal the mechanisms of action of these selective agonists in the CNS and on gut hormones.
Methods

Animals and diets
The care and use of the animals and the experimental protocols used in this study were approved by the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company, Ltd. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Every effort was made to minimize animal suffering and to reduce the number of animals used.
Male C57BL/6J mice were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan) or CLEA Japan, Inc. (Tokyo, Japan), and fed a standard rodent food (CE-2; CLEA Japan, Inc.) unless otherwise indicated. To induce obesity, mice were fed a HFD (D12331, 58% energy from fat; Research Diets Inc., New Brunswick, NJ, USA) beginning at 5 weeks of age until the end of the study. Male B6.Cg-Lep ob /J mice (ob/ob mice) were purchased at 7 weeks of age from Charles River Laboratories Japan, Inc., and fed a HFD (D12451, 45% energy from fat; Research Diets Inc.) beginning at 10 weeks of age until the end of the study. Animals had ad libitum access to food and water unless otherwise stated. The animals were housed individually under controlled temperature (20-26°C) and humidity (40-70%) and a 12 h light-dark cycle (lights on at 0700 h). C57BL/6J mice show impaired glucose tolerance and are mostly used in obesity and diabetes research (Toye et al., 2005) ; ob/ob mice are leptin-deficient and are used in obesity and diabetes research, and HFD feeding has been used for years to induce obesity (Tschöp and Heiman, 2001) .
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Peptides
PEGylated NmU-8 (NMU-0002, Inooka et al., 2017) and a PEGylated NMU2 receptor-selective agonist (NMU-2084 , Kanematsu-Yamaki et al., 2017 were synthesized at Takeda Pharmaceutical Company, Ltd. Alkylated and an alkylated NMU1 receptor-selective agonist (NMU-6102) were synthesized using standard fluorenylmethoxycarbonylbased solid-phase synthetic methods. Subsequent preparative HPLC purification of the obtained crude peptides indicated that they had ≥95% homogeneity. The purity of each peptide was verified by analytical reversed-phase HPLC, and each structure was assigned using matrix-assisted laser desorption/ionization time-of-flight MS.
In vitro agonist activity 
Plasma parameter measurements
Plasma glucose, triglycerides, total cholesterol, aspartate aminotransferase (ALT) and alanine aminotransferase (AST) were measured using an Autoanalyser 7180 (Hitachi HighTechnologies Corporation, Tokyo, Japan). Glycated Hb (GHb) was measured using an automated glycohaemoglobin analyser (HCL-723G7; Tosoh, Tokyo, Japan). Plasma insulin was measured using the Rat Insulin RIA Kit (LINCO Research, St. Charles, MO, USA).
Four-week treatment of DIO mice with non-selective NMU-0002
At the age of 27 weeks, male DIO C57BL/6J mice were singly housed and received a 7 day habituation to handling and s.c. dosing. The mice were non-blindly randomized into experimental groups matched for BW, FI and plasma parameters, with similar variances. Vehicle (saline) or NMU-0002 (3, 10 and 30 nmol·kg À1 ) were s.c. administered for 4 weeks.
BW and FI were monitored during the study. BWs are visualized as percentage of initial BW for comparison with other drugs as described previously (Mack et al., 2010) . Body composition was measured on days 14 and 27 using a whole body composition analyser (EchoMRI-900; Hitachi Aloka Medical, Ltd., Tokyo, Japan). On day 27, blood was collected, and plasma parameters were measured. On day 28, an oral glucose tolerance test (OGTT) was performed. Briefly, overnight fasted mice were subjected to p.o. glucose load (2 g·kg À1 ).
Plasma glucose and insulin levels were measured in blood samples collected before (0 min) and 10, 30, 60 and 120 min post-glucose load. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated using the following formula: [fasting glucose (mmol·L À1 ) × fasting insulin (μU·mL À1 )/22.5] as described previously (Matthews et al., 1985) . The liver and adipose tissues were dissected and weighed on day 29. 
Diarrhoea scoring
A scoring system to assess diarrhoea severity was developed based on a 3-point scale: 0, solid, normal stool; 1, formed stools, less firm, that appear moist on the outside; and 2, no formed stools or liquid stool with very minimal solids. A single observer scored the stools during the study in a blinded manner. Data are expressed as mean scores and SD.
Nocturnal feeding studies in mice
At the age of 8 weeks, male C57BL/6J mice were singly housed and received a 7 day habituation to handling and s.c. dosing. The mice were non-blindly randomized into experimental groups matched for FI and BW with similar variance. Mice were then treated with a single s. administered once a day for 2 weeks. BW and FI were monitored during the study. In the former study, body composition was measured on day 13 using EchoMRI-900, followed by plasma parameter measurements on day 14. In the latter study, plasma parameters were measured on day 12, and OGTT was performed in overnight-fasted mice on day 13.
Glucose tolerance test in ob/ob mice
The OGTT and i.p. glucose tolerance test (ipGTT) were performed 2 h after a single s.c. administration of vehicle (saline) or NMU-0002 (10 or 100 nmol·kg À1 ). Overnight-fasted ob/ob mice (8 or 13 weeks of age) were non-blindly randomized into groups matched for GHb, fasting plasma glucose and BW, with similar variance. Plasma glucose levels were measured before (0 min) and 10, 30, 60 and 120 min after p.o. or i.p. glucose load (1 g·kg À1 ).
Pharmacokinetics
Male C57BL/6J mice (8 or 9 weeks of age) were treated with a single s.c. injection of NMU-0002 (10 nmol·kg À1 ), NMU-6014 (50 nmol·kg À1 ), NMU-6102 (300 nmol·kg À1 ) or NMU-2084 (10 nmol·kg À1 ). Blood samples were collected at 0-48 h and centrifuged to obtain plasma. Plasma samples were deproteinized using methanol or acetonitrile. After centrifugation, the supernatants were analysed using an LC/MS/MS system (API5000; Applied Biosystems, Foster City, CA, USA) to determine plasma concentrations of the compounds. For plasma samples obtained from animals treated with NMU-0002 and NMU-2084, the supernatants were transferred into 96-well microtitre plates after deproteinization and evaporated to dryness under a steady stream of nitrogen gas. The residuals were reconstituted in a mixture of acetonitrile and distilled water. An aliquot sample was also injected into the LC/MS/MS system to determine the plasma concentrations of the compounds. The pharmacokinetic parameters were calculated using the moment analysis method and expressed as dose-normalized values for comparison with other drugs.
c-Fos immunohistochemistry
Male C57BL/6J mice (9 or 12 weeks of age) on a standard rodent food were singly housed and received a 7 day habituation to handling and i.p. dosing. The mice were non-blindly randomized into experimental groups matched for BW with similar variance and fasted for 25 h. These mice were treated with a single i.p. injection of vehicle (10% DMSO/saline), NMU-0002 (10 or 30 nmol·kg À1 ) or NMU-6014 (100 or 300 nmol·kg À1 ). In a separate study, male C57BL/6J mice were treated with a single i.p. injection of vehicle (10% DMSO/saline), NMU-6102 (300 or 1000 nmol·kg À1 ) or NMU-2084 (300 or 1000 nmol·kg À1 ). After 3 h, the animals were deeply anaesthetized with an overdose of pentobarbitone, and the brains were dissected, fixed in Mildform 10N (Wako) at 4°C overnight and cryoprotected in 30% sucrose in PBS. The brains were then frozen using O.C.T. compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan). Fortymicrometre-thick coronal sections from each brain area [nucleus of the solitary tract (NTS), area postrema (AP), arcuate nucleus (ARC) and PVN] were prepared. Sections from the NTS and AP were incubated with rabbit anti-c-Fos antibody (1:1000, sc-52; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and sections from the ARC and PVN were incubated with rabbit anti-c-Fos antibody (1:4000, sc-253; Santa Cruz Biotechnology, Inc.) after in situ hybridization (ISH) (described below), and then c-Fos expression was visualized using the VECTASTAIN Elite ABC Kit (PK-6101; Vector Laboratories Inc., Burlingame, CA, USA) and ImmPACT diaminobenzidine (SK-4105; Vector Laboratories Inc.). All of the procedures were performed using the free-floating method. Sections were mounted, and images were acquired using light microscopy (Axioimager M1; Carl Zeiss, Munich, Germany) and/or NanoZoomer (Hamamatsu Photonics, Hamamatsu, Japan) using a 20× objective lens for the ARC and PVN and a 10× objective lens for the NTS and AP.
In situ hybridization for Pomc
The cDNA fragment of the Pomc gene was obtained by PCR and subcloned into the pCR-Blunt II-TOPO vector (K280020; Invitrogen). Digoxygenin (DIG)-labelled riboprobes were produced by in vitro transcription using the SP6/T7 Transcription Kit (1175025; Roche Diagnostics, Mannheim, Germany) with the plasmid as a template. During ISH, all of the procedures were performed using the freefloating method. Coronal frozen sections (40 μm thick, as described above) of the ARC were acetylated and then incubated overnight in a hybridization buffer containing DIG-labelled riboprobes (Pomc) at 60°C. After hybridization, the sections were washed, incubated with alkaline phosphataseconjugated anti-DIG antibody (1:1000, 11093274910; Roche Diagnostics) for 2 h at 37°C and then visualized using a chromogen solution containing 4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indoyl-phosphate. After being rinsed with PBS, the sections underwent double staining with c-Fos as described above.
Neuroanatomical quantitative analyses
In 
Plasma corticosterone measurements in mice
At the age of 8 weeks, male C57BL/6J mice singly housed were received a 7 day habituation to handling and i.p. dosing. Mice were non-blindly randomized into groups matched for BW with similar variance. Mice were i.p. injected with vehicle (saline), NMU-0002 (10, 30 or 100 nmol·kg À1 ) or NMU-2084
(300 or 1000 nmol·kg À1 ). After 3 h, blood samples were collected into collection tubes containing aprotinin and EDTA. Blood samples were centrifuged, and plasma was used to measure corticosterone levels using the Corticosterone EIA Kit (YK240; Yanaihara Institute Inc., Shizuoka, Japan).
Oral oil tolerance test in DIO mice
At the age of 42 weeks, male DIO C57BL/6J mice were singly housed and received a 7 day habituation to handling and 
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are expressed as means ± SD. Statistical significance was analysed using oneway ANOVA with post hoc Dunnett's multiple-comparison test, and differences with P ≤ 0.05 were regarded as significant. Post hoc tests were run only when F achieved P < 0.05. Analyses were performed using SAS System Version 8.2 (SAS Institute Japan Ltd., Tokyo, Japan) or EXSUS version 8.0 (CAC Croit Corporation, Tokyo, Japan).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
Anti-obesity effects of 4 week treatment with non-selective NMU-0002 in DIO mice
We recently discovered that PEGylated NmU-8 (designated NMU-0002) has enhanced in vivo pharmacological actions due to improved pharmacokinetics (Inooka et al., 2017) with little effect on the ratio of mouse NMU1 to NMU2 receptor agonism when compared with native NmU-8 (Table 1) . NMU-0002 had BW-lowering effects ( Figure 1A ) accompanied by FI inhibition ( Figure 1B ) in a dose-dependent manner in DIO mice s.c. administered with NMU-0002 (3, 10 or 30 nmol·kg À1 ) once daily for 4 weeks. Body composition analysis revealed fat mass was significantly reduced ( Figure 1C) , and a small but significant reduction in non-fat mass was evident at week 2 but not at week 4 ( Figure 1D ). Consistently, the liver and white fat tissue weights were significantly reduced after 4 weeks ( Figure 1E ). NMU-0002 significantly lowered plasma glucose, insulin, total cholesterol, ALT and AST in a dose-dependent manner (Supporting Information Table S1 ). An OGTT after 4 week NMU-0002 treatment revealed a dose-dependent improvement in glucose tolerance and reduction in plasma insulin levels (Supporting Information Figure S1A -C), resulting in a reduced insulin resistance index (HOMA-IR) (Supporting Information Figure S1D ). Diarrhoea was observed for the first 2 days after dosing with NMU-0002 at 10 and 30 nmol·kg À1 .
Anti-obesity and diabetic effects of 2 week treatment with non-selective NMU-0002 in ob/ob mice
To examine the anti-obesity and diabetic effects of NMU-0002, it was s.c. administered once daily for 2 weeks in obese and T2DM leptin-deficient ob/ob mice fed a HFD. NMU-0002 at 30 and 100 nmol·kg À1 had BW-lowering effects (Figure 2A ) accompanied by FI inhibition ( Figure 2B ) in a dose-dependent manner. Body composition analysis revealed fat mass was significantly reduced in these mice, and a small 
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but significant reduction in non-fat mass was also evident ( Figure 2C ). In line with this, NMU-0002 significantly improved plasma parameters in a dose-dependent manner (Supporting Information Table S2 ). These results indicate that NMU-0002 has anti-obesity and anti-diabetic effects in obese and T2DM model mice. However, diarrhoea also occurred in HFD-fed ob/ob mice treated with NMU-0002 (100 nmol·kg À1 ) for the first 7 days. To examine whether acute NMU-0002 treatment improves glucose tolerance, OGTT and ipGTT were performed in ob/ob mice. A single s.c. administration of NMU-0002 (100 nmol·kg À1 ) reduced glucose excursion during OGTT ( Figure 2D ) but surprisingly not during ipGTT ( Figure 2E ), suggesting that NMU-0002 might inhibit glucose absorption. Therefore, NMU-0002 might act on NMU1 receptors expressed in the gastrointestinal tract, which would account for the observed diarrhoea and inhibition of glucose absorption.
Anti-obesity effects of 2 week treatment with NMU1 and NMU2 receptor-selective agonists in DIO mice
To determine the role of NMU1 and NMU2 receptors in the anti-obesity and adverse effects (i.e. diarrhoea) of Differential effects of NMU1/2-selective agonists BJP NMU-0002, we used selective agonists to the NMU1 receptor (designated NMU-6102) and NMU2 receptor (designated NMU-2084) identified in-house (Table 1) . As NMU-6102 is an alkylated peptide (Table 1) , an alkylated non-selective agonist NMU-6014 was also used for comparison. Before conducting long-term treatment studies in DIO mice, acute effects of these agonists on FI were assessed in normal mice (Supporting Information Figure S2 ). To achieve similar effects to NMU-0002 (20 nmol·kg À1 ), NMU-6014 required an approximately fivefold higher dose, and NMU-6102 and NMU-2084 required a 30-fold higher dose, presumably due to weaker in vitro activities for NMU1 and NMU2 receptors (Table 1) and/or less exposure to the circulation on a per-dose basis (Supporting Information Figure S3 and Table S3 ). The agonists were s.c. administered in DIO mice once daily for 2 weeks at the doses selected based on these findings. NMU-6102 had BW-lowering effects ( Figure 3A ) accompanied by FI inhibition ( Figure 3B ) in a dose-dependent manner. However, NMU-6102-mediated BW loss on day 14 (11.1% loss, even at 1000 nmol·kg À1 ) was less potent than Figure 3C ). Contrary to NMU-6102, NMU-2084 had potent BW-lowering effects (13.8% loss at 300 nmol·kg À1 on day 14) accompanied by anorectic effects in a dose-dependent manner ( Figure 3D, E) . Moreover, the diarrhoea score observed after NMU-2084 treatment was better than that after NMU-0002 treatment. Thus, NMU-0002 (10 nmol·kg À1 ) and NMU-2084 (100 nmol·kg À1 ) had similar anti-obesity effects, but NMU-2084 had much lower diarrhoea scores ( Figure 3F ).
Anti-obesity and diabetic effects of 2 week treatment with NMU1 and NMU2 receptor-selective agonists in ob/ob mice
To examine the anti-obesity and diabetic effects of NMU1 and NMU2 receptor-selective agonists, NMU-6102 or NMU-2084 was s.c. administered once daily for 2 weeks in HFD-fed ob/ob mice. NMU-0002 (30 nmol·kg À1 ) and NMU-6102 (1000 nmol·kg À1 ) had BW-lowering effects ( Figure 4A )
Figure 4 Differential effects of NMU1/2-selective agonists BJP accompanied by FI inhibition ( Figure 4B ). NMU-2084 (1000 nmol·kg À1 ) led to a small but significant reduction in FI; however, NMU-2084 unexpectedly did not affect BW ( Figure 4A, B) . Plasma glucose, GHb and insulin were significantly reduced ( Figure 4C -E), and glucose tolerance was improved by NMU-0002 and NMU-6102 but not NMU-2084 (Figure 4F, G) . This suggests that the anti-diabetic effect of NMU-0002 was mediated at least partly by its anti-obesity effects and the inhibition of glucose absorption via NMU1 receptor agonism. These results suggest that NMU1 receptor-selective but not NMU2 receptor-selective agonists are effective in T2DM model mice.
c-Fos expression in the hypothalamus induced by NMU1 and NMU2 receptor-selective agonists
To gain mechanistic insights into how peripherally administered selective agonists to NMU1 and NMU2 receptors exert their differential actions, protein expression of c-Fos induced by the agonists was examined in ARC POMC neurons and in the PVN, which are important areas for feeding control. We examined POMC-positive neurons in the ARC in particular, since the activation of these neurons mediates anorexic response. We also assessed c-Fos levels in the NTS and AP, which are key hindbrain areas involved in processing inputs related to satiety and nausea. NMU-0002 (30 nmol·kg À1 )
and NMU-6014 (300 nmol·kg À1 ) activated POMC-expressing neurons in the ARC and increased c-Fos-immunoreactive cell numbers in the PVN ( Figure 5A, B) , the NTS and AP (Supporting Information Figure S4A , B) in a dose-dependent manner. NMU1 receptor-selective NMU-6102 increased c-Fos-immunoreactive cell numbers in the PVN ( Figure 5C, D) , the NTS and AP (Supporting Information Figure S4C , D) in a dose-dependent manner but did not activate the POMCexpressing neurons in the ARC ( Figure 5C, D) . However, NMU2 receptor-selective NMU-2084 activated the POMCexpressing neurons in the ARC ( Figure 5C , D) and the neurons in the NTS and AP (Supporting Information Figure S4C , D) but did not affect the PVN ( Figure 5C , D). These data suggest that peripherally administered NMU2 receptorselective agonists activate POMC neurons directly via NMU2 receptors in the ARC, or indirectly, to exert their anti-obesity effects.
To gain further mechanistic insights, plasma gut hormone levels were examined in lean mice. PYY levels were significantly increased (Supporting Information Figure S5 ), and desacyl-ghrelin (stable form of ghrelin reflecting active acylated-ghrelin levels) and CCK were significantly decreased by NMU-0002, NMU-6014 and NMU-6102, but not by NMU-2084, indicating that the NMU1 receptor is involved in changes in plasma gut hormone levels.
Discussion
We assessed the pharmacological efficacies and adverse effects (diarrhoea) of peripherally administered NMU1 receptor-selective and NMU2 receptor-selective agonists along with non-selective agonists in mouse models of obesity and diabetes. We found that the NMU2 receptor-selective agonist had a more potent BW-lowering effect and caused less diarrhoea than the NMU1 receptor-selective agonist did in DIO mice. In addition, the NMU2 receptor-selective agonist preferentially activated the hypothalamic ARC POMC neurons but not neurons in the PVN. However, the NMU1 receptor-selective agonist and the non-selective agonists were effective in leptin-deficient diabetic ob/ob mice and affected gut hormones in normal mice, in contrast to the NMU2 receptor-selective agonist, which had little effect on these measures. Therefore, we propose that an NMU2 receptorselective agonist is a well-balanced drug for the treatment of obesity in terms of both its efficacy and safety and that an NMU1 receptor-selective agonist may also be beneficial for the treatment of obesity and diabetes once its side effects are minimized.
The NMU1 receptor-selective agonist NMU-6102 had limited efficacy in DIO mice when compared with the nonselective agonists NMU-0002 and NMU-6014, and the NMU2 receptor-selective NMU-2084, suggesting that NMU2 receptor-selective agonists may be superior to NMU1 receptor-selective agonists in lowering BW. The limited efficacy of the NMU1 receptor-selective agonist might be owing to the lower contribution of NMU1 receptors to the regulation of feeding behaviour and BW control. Indeed, previous studies have shown that peripherally long-acting NmU analogues do not have lasting effects in NMU2 receptor KO mice but do in NMU1 receptor KO mice (Ingallinella et al., 2012; Neuner et al., 2014) . Our results further highlight that NMU2 receptor-selective agonists are most efficacious.
Mechanistically, peripherally administered NMU1 receptor-and NMU2 receptor-selective agonists showed different neural activation patterns, as shown by c-Fos protein immunohistochemistry in the hypothalamus. Although NMU2 receptor mRNA is expressed in both the ARC and PVN (Graham et al., 2003; Dalbøge et al., 2015b) and central NmU activates both the ARC and PVN (Niimi et al., 2001; Ivanov et al., 2002; Ozaki et al., 2002; Hanada et al., 2004) , peripherally administered NMU2 receptor-selective NMU-2084 activates ARC POMC neurons but not neurons in the PVN. These results strongly suggest that central and peripheral administration result in the activation of different pathways. We hypothesize that peripherally administered NMU2 receptor agonists can directly activate NMU2 receptors expressed in the ARC, which is located at the base of the median eminence, lacks a blood-brain barrier and can be accessed by circulating factors (Broadwell and Brightman, 1976; Suzuki et al., 2012) , while it does not penetrate the PVN; however, this hypothesis is yet to be tested experimentally. In contrast, the NMU1 receptor-selective agonist activates the PVN, but not POMC neurons in the ARC, presumably via peripherally expressed NMU1 receptors and ascending projections, as NMU1 receptor expression is very low in the hypothalamus (Rønnekleiv et al., 2014) . This differential neural activation in the PVN by NMU1/2 receptor agonists was associated with changes in plasma corticosterone levels, which were elevated by NMU1/2 receptor non-selective NMU-0002 but not by NMU2-selective NMU-2084 (Supporting Information Figure  S6 ). These results provide us with mechanistic insights into how NMU1 receptor-and NMU2 receptor-selective agonists act differently: the NMU2 receptor-selective agonist preferentially activates POMC neurons to exert its anorectic effects, while the NMU1 receptor-selective agonist activates the PVN, which might lead to unwanted effects, such as a stress response (discussed below). This might also account for the different efficacies of the two compounds in DIO mice. Consistent with a previous report (Peier et al., 2011) , plasma PYY levels were increased. Additionally, we found that CCK and desacyl-ghrelin were decreased in an NMU1 receptor-dependent manner. The increases in PYY and GLP-1 are not responsible for the acute NmU-mediated effects on FI and BW (Peier et al., 2011) . The significance of the decreased CCK and ghrelin levels is unclear. As ghrelin is the only known orexigenic gut hormone, it is plausible that decreased ghrelin is associated with the anorectic effect of NMU1 receptor agonism. However, reduced CCK is discrepant with the known functions of NmU [FI inhibition (Martinez and O'Driscoll, 2015) and gastric emptying (Dalbøge et al., 2015b) ], suggesting that CCK is not involved in such NmU-mediated functions. It is also unknown how NMU1 receptor agonism affects plasma levels of these gut hormones. NMU1 receptor mRNA is detected in the mucosal lamina propria throughout the entire gut and scattered in cells of the gastric mucosa (Dalbøge et al., 2015b) . It is thus possible that NMU1 receptor agonists directly modulate the secretion of these gut peptides.
A single central administration of NmU exerts anorectic effect in ob/ob mice and db/db mice (Hanada et al., 2004) , and a single peripheral administration of NmU also leads to anorectic effect in db/db mice (Peier et al., 2011) . Leptin appears unimportant for this effect. Consistent with this idea, non-selective NMU-0002 and NMU1 receptor-selective NMU-6102 showed prominent anorectic and BW-lowering effects in ob/ob mice following repeated peripheral dosing. In contrast, NMU2 receptor-selective NMU-2084 was less effective, suggesting that leptin signalling might be required for long-term peripheral NMU2 receptor agonist actions. Nonetheless, our data clearly demonstrate that NMU-2084 is effective in DIO mice, which are known to be resistant to peripheral leptin (Van Heek et al., 1997; El-Haschimi et al., 2000) . This suggests that NMU2 receptor agonism might activate central leptin signalling to exert its anorectic effect. Future investigations are required to elucidate how the leptin signal works in concert with NMU2 receptors. Since NMU-0002 did not increase plasma leptin levels (Supporting Information Figure S7 ), focusing on the effects of NMU2 receptor agonism and leptin in POMC neurons in the ARC would provide us with valuable mechanistic insight.
During both OGTT and ipGTT in DIO mice, a single peripheral administration of native NmU and PEG-NmU improves glucose tolerance via NMU1 receptors (Peier et al., 2011) and NMU2 receptors (Ingallinella et al., 2012) , respectively, suggesting that different pharmacokinetics result from different pharmacodynamics. As expected, a single peripheral administration of NMU-0002 lowered glucose excursion during OGTT in ob/ob mice. However, NMU-0002 did not have any effect during ipGTT. This unanticipated result suggests that NMU1/2 receptor non-selective agonists might inhibit glucose absorption. One possibility is that NmU mediates the regulation of mucosal functions, such as intestinal motility, ion transport, absorptive/secretory function (Brown and Quito, 1988; Brighton et al., 2004) and prokinetic activity via NMU1 receptors (Dass et al., 2007) . Further studies are obviously required to explain the discrepancies between previous results (Peier et al., 2011; Ingallinella et al., 2012) and ours (e.g. differences in experimental conditions, such as different mouse strains used) and to determine the mechanisms underlying our observations (e.g. by using receptortype selective agonists).
Side effects should be given careful consideration when developing a therapeutic agent. Several potential side effects of compounds modifying NMU1/2 receptor activity can be assumed. These include nociception (Zeng et al., 2006) , stress response (Martinez and O'Driscoll, 2015) and a sense of malaise (Peier et al., 2011) , which may affect feeding behaviour, although it is unclear whether these findings are clinically relevant. The stress response induced by direct injection of NmU into the PVN does not necessarily lead to its anorectic effect (Thompson et al., 2004) , and long-term central or peripheral administration of NmU does not elevate endpoint plasma corticosterone levels (Peier et al., 2009 (Peier et al., , 2011 . As described above, we observed elevated plasma corticosterone levels following a single administration of NMU1/2 receptor non-selective agonists but not with the NMU2 receptorselective agonist (Supporting Information Figure S6 ). This suggests that acute peripheral NMU1 receptor agonism stimulates the hypothalamic-pituitary-adrenal axis. We also observed that NmU receptor agonists cause diarrhoea, especially during the first week of dosing with NMU1 receptor-selective NMU-6102, which had a more apparent effect than NMU2 receptor-selective NMU-2084. The mechanism underlying this effect remains unknown. NmU promotes ion secretion (Brown and Quito, 1988) and small intestinal transit (Nakashima et al., 2010) , and NMU1 receptor agonism is considered to increase colonic motility (Dass et al., 2007) , again raising the possibility that NMU1 receptor agonism might directly cause diarrhoea by affecting the gastrointestinal tract. In addition, since diarrhoea was observed only in HFD-fed animals but not in normal chow diet-fed animals, NmU receptor agonists may cause diarrhoea upon HFD feeding. We thus examined the effects of NMU1/2 nonselective agonists on fat absorption in DIO mice that were well acclimatized to HFD and found that acutely administered non-selective agonists inhibited fat absorption (Supporting Information Figure S8 ). NMU1 receptors may also have indirect action through PVN activation and CRH, which is known to be linked to diarrhoea (Mayer, 2000; Mönnikes et al., 2001; Mayer et al., 2008; Stengel and Taché, 2009 ). Finally, non-fat mass reduction by NMU-0002 ( Figures 1D and 2C ) requires future investigation to understand whether NmU receptor agonists induce muscle mass loss, which is detrimental to obesity and diabetes therapy. The present study had several limitations; for instance, we could not identify the neuronal subtypes activated by NMU-0002 and NMU-6014 in the PVN; our results do not exclude the possibility of NmU receptor agonist toxicity, which is not manifested by the diarrhoea score; moreover, drug concentrations in the hypothalamus were too low to be precisely quantified.
In summary, we showed differential effects of selective agonists for NMU1 and NMU2 receptors following peripheral administration in mouse models of obesity and diabetes. These data suggest that the NMU2 receptor-selective agonist would be a well-balanced drug for the treatment of obesity in terms of efficacy and safety and that the NMU1 receptor-BJP H Nagai et al.
selective agonist could also be beneficial for obesity and diabetes once its side effects are minimized. Recently, we reported a novel NMU2 receptor-selective agonist, NMU-7005, and its pharmacological effects in mice Kanematsu-Yamaki et al., 2017) . These selective agonists will be useful in unravelling the multiple functions of NmU in different pathophysiological contexts. Valsamakis G, Konstantakou P, Mastorakos G (2017 
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https://doi.org/10.1111/bph.14077 Table S1 Effects of non-selective agonist NMU-0002 treatment on plasma parameters in diet-induced obese (DIO) mice. Plasma parameters in DIO mice maintained on a HFD and treated for 4 weeks with vehicle or non-selective NMU-0002 (3, 10, or 30 nmol·kg À1 ). Compounds were administered by daily subcutaneous injection. Data represent means-± SD; n = 6; * P < 0.05, versus vehicle by one-way ANOVA with Dunnett's multiple-comparison test. Table S2 Effects of treatment with non-selective agonist NMU-0002 on plasma parameters in HFD-fed ob/ob mice. Plasma parameters in ob/ob mice maintained on a HFD and treated for 2 weeks with vehicle or non-selective NMU-0002 (30 or 100 nmol·kg À1 ). Compounds were administered by daily subcutaneous injection. Data represent means ± SD; n = 8, except for NMU-0002 (100 nmol·kg À1 ) where n = 6; * P < 0.05, versus vehicle by one-way ANOVA with Dunnett's multiple-comparison test. Table S3 Pharmacokinetic parameters of non-selective and selective agonists for NMU1/2 receptors. The parameters were calculated from the mean of plasma concentrations (n = 3) and shown as dose-normalized values. AUC, area under the curve; MRT, mean residence time. The parameters of NMU-0002 are from Inooka et al., 2017 . Figure S6 Acute effects of NMU1/2 receptor agonists on plasma corticosterone levels in mice. Plasma corticosterone levels were measured in mice 3 h after a single intraperitoneal administration of the indicated NMU1/2 receptor agonists at the indicated doses (nmol·kg À1 ). Data represent means + SD; n = 3-5 as indicated in the graph. Figure S7 Acute effects of NMU-0002 on plasma leptin levels in normal, lean, mice. Plasma levels of leptin were measured in male C57BL/6J mice 4 h after a single subcutaneous administration of non-selective NMU-0002 (100 nmol·kg À1 ). Data represent means ± SD; n = 6. The change was not statistically significant, as assessed by Student's t-test. Figure S8 Effects of NMU-0002 and NMU-6014 on triglyceride absorption in diet-induced obese (DIO) mice. Plasma levels of triglycerides (TGs) were measured at the indicated time after oral administration of olive oil (2 mL·kg À1 ) in male DIO-C57BL/6J mice 2 h after a single subcutaneous administration of non-selective NMU-0002 (30 nmol·kg À1 ) or NMU-6014 (150 nmol·kg À1 ). Data represent means ± SD; n = 5.
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